Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,520.00-0.35%ETH$2,697.04-0.63%GOLD$4,189.90+0.07%OIL$89.91+0.53%
Smart Investors Daily
SID Premium
XR

NASDAQ · XRTX

XORTX Therapeutics Inc.

Healthcare · Biotechnology

$1.73

Up+$0.03 (+1.76%)

Updated Oct 7, 2026, 2:03 AM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.34M
P/E ratio
-1.24
Dividend yield
0.00%
52-week range
$1.59 – $7.05
Volume
40.94K
Avg. volume
1.97M

Price performance · XRTX

XRTX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

XRTX closed at $1.73 after 21 trading sessions, down 24.12% for the selected period.

Last close
$1.73
Period change
-24.12%
Period low
$1.66
Period high
$2.33
Daily close
View OHLC price history
XRTX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$1.75$1.7884$1.71$1.7340.94K
Oct 5, 2026$1.73$1.73$1.69$1.708.94K
Oct 2, 2026$1.7169$1.7946$1.70$1.71424.48K
Oct 1, 2026$1.69$1.75$1.69$1.7322.08K
Sep 30, 2026$1.70$1.72$1.69$1.6926.08K
Sep 29, 2026$1.70$1.74$1.69$1.7071.43K
Sep 28, 2026$1.69$1.7414$1.69$1.7130.01K
Sep 25, 2026$1.74$1.82$1.69$1.6946.86K
Sep 24, 2026$1.69$1.78$1.69$1.7251.34K
Sep 23, 2026$1.80$1.8302$1.69$1.7059.42K
Sep 22, 2026$1.91$1.93$1.78$1.8679.64K
Sep 21, 2026$1.99$2.09$1.85$1.95227.45K
Sep 18, 2026$1.95$2.65$1.74$1.927.22M
Sep 17, 2026$1.75$1.78$1.5901$1.662.24M
Sep 16, 2026$1.85$1.85$1.765$1.7849.6K
Sep 15, 2026$2.05$2.07$1.81$1.8895.13K
Sep 14, 2026$2.02$2.28$1.9401$2.07176.68K
Sep 11, 2026$2.41$2.45$2.17$2.331.92M
Sep 10, 2026$2.4499$2.45$2.11$2.111.53M
Sep 9, 2026$2.26$2.31$2.15$2.15814.89K
Sep 8, 2026$2.1937$2.38$2.1937$2.289.97K

Latest XRTX news

The latest Smart Investors Daily articles mentioning XRTX.

Stock researchCompany · Overview

XRTX research

Overview

Company profile and research snapshot.

Company profile

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
XRTX recent ratings
DateFirmRatingTarget
May 8, 2023ALLIANCE GLOBAL PARTNERSBuy—
May 7, 2023ALLIANCE GLOBAL PARTNERSBuy—
Apr 10, 2023ALLIANCE GLOBAL PARTNERSBuy—
Apr 22, 2022Alliance Global PartbersBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 18, 2026

XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity

Investigational New Drug application planned for submission to the U.S. FDA in the fourth quarter of 2026, advancing the Company’s regulatory path toward NDA filing for gout program XRx-026CALGARY, Alberta, Sept. 18, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, outlines its anticipated Investigational New Drug applica

Benzinga · Sep 14, 2026

12 Health Care Stocks Moving In Monday's Pre-Market Session

Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 44.6% to $2.4 during Monday's pre-market session. The company's market cap stands at $1.1 million. Definium Therapeutics (NASDAQ:DFTX)

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By